RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients with metastatic renal cell carcinoma (mRCC): anti-vegf cohort subanalysis

被引：0
|
作者：
Cosgriff, Thomas [1 ]
Yang, Lin [2 ]
Alyasova, Anna [3 ]
Ye, Dingwei [4 ]
Karpenko, Andrey [5 ]
Alekseev, Boris [6 ]
Kowalyszyn, Ruben [7 ]
Karyakin, Oleg [8 ]
Neron, Yeni [9 ]
Collins, La T. [10 ]
Brechenmacher, Thomas [11 ]
Lin, Chinjune [10 ]
Morgan, Liza [10 ]
Motzer, Robert [12 ]
机构：
[1] Crescent City Res Consortium, Metairie, LA USA
[2] Chinese Acad Med Sci, Canc Inst & Hosp, Beijing, Peoples R China
[3] Prevoljskiy Reg Med Ctr, Novgorod, Russia
[4] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Moscow Hertzen Oncol Inst, St Petersburg, Russia
[6] Moscow Hertzen Oncol Inst, Moscow, Russia
[7] Clin Viedma, Ctr Invest Clin, Viedma, Rio Negro, Argentina
[8] Med Radiol Res Ctr, Dept Oncol, Obninsk, Russia
[9] Ctr Pesquisas Oncol CEPON, Florianopolis, SC, Brazil
[10] Novartis Oncol, E Hanover, NJ USA
[11] Novartis Pharma SAS, Rueil Malmaison, France
[12] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
BJU INTERNATIONAL | 2016年 / 118卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：23 / 24
页数：2
相关论文
共 50 条
  • [31] EVEROLIMUS (EVE) IN RECORD-1 ELDERLY PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) AND MANAGEMENT OF RELATED ADVERSE EVENTS (AES)
    Calvo, E.
    Porta, C.
    Escudier, B.
    Ravaud, A.
    Oudard, S.
    Osanto, S.
    Bracarda, S.
    Gruenwald, V.
    Vaishampayan, U.
    Climent, M. A.
    Berg, W. J.
    Lebwohl, D.
    Motzer, R. J.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 63 - 64
  • [32] Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE) and LEN plus EVE in metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Dutcus, Corina E.
    Ren, Min
    Baig, Mahadi Ali
    Fishman, Mayer N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Everolimus (E) versus axitinib (A) as second-line therapy (2L) in metastatic renal cell carcinoma (mRCC): Retrospective experience at Gustave Roussy.
    Guida, Annalisa
    Albiges, Laurence
    Loriot, Yohann
    Massard, Christophe
    Fizazi, Karim
    Escudier, Bernard J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [34] A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)
    Gruenwald, Viktor
    Hilser, Thomas
    Meiler, Johannes
    Goebell, Peter J.
    Ivanyi, Philipp
    Strauss, Arne
    Hartmann, Arndt
    Bedke, Jens
    Bergmann, Lothar
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05) : 272 - 280
  • [35] Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx
    Tsimafeyeu, Ilya
    Borisov, Pavel
    Abdelgafur, Ahmed
    Leonenkov, Roman
    Novikova, Olga
    Guseva, Irina
    Demchenkova, Marina
    Mikhailova, Nadezhda
    Semenov, Andrey
    Yurmazov, Zakhar
    Sivunova, Irina
    Ramazanova, Madina
    Gamayunov, Sergey
    Kosov, Dmitry
    Bratslavsky, Gennady
    [J]. TARGETED ONCOLOGY, 2019, 14 (01) : 33 - 38
  • [36] Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx
    Ilya Tsimafeyeu
    Pavel Borisov
    Ahmed Abdelgafur
    Roman Leonenkov
    Olga Novikova
    Irina Guseva
    Marina Demchenkova
    Nadezhda Mikhailova
    Andrey Semenov
    Zakhar Yurmazov
    Irina Sivunova
    Madina Ramazanova
    Sergey Gamayunov
    Dmitry Kosov
    Gennady Bratslavsky
    [J]. Targeted Oncology, 2019, 14 : 33 - 38
  • [37] Everolimus (EVE) versus temsirolimus (TEM) after first-line treatment with VEGF TKI in patients with metastatic renal cell carcinoma
    Patel, Shiven B.
    Agarwal, Neeraj
    Hsu, JoAnn
    Tantravahi, Srinivas Kiran
    Gill, David
    Vuong, Winston
    Batten, Julia A.
    Stenehjem, David D.
    Pal, Sumanta Kumar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [38] Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).
    Cella, D.
    Escudier, B.
    Rini, B. I.
    Chen, C.
    Bhattacharyya, H.
    Tarazi, J. C.
    Rosbrook, B.
    Kim, S.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts)
    Al-Marrawi, M. Y.
    Rini, B. I.
    Harshman, L. C.
    Bjarnason, G. A.
    Wood, L.
    Vaishampayan, U. N.
    MacKenzie, M. J.
    Knox, J. J.
    Agarwal, N.
    Kollmannsberger, C. K.
    Tan, M.
    Rha, S. Y.
    Donskov, F.
    North, S. A.
    Choueiri, T. K.
    Heng, D. Y. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Cabopoint: a phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
    Ivanyi, P.
    Albiges, L.
    Schmidinger, M.
    Taguieva-Pioger, N.
    Perol, D.
    Gruenwald, V
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 274 - 274
12345